Changes in Mood, Anxiety, and Cognition with Polycystic Ovary Syndrome Treatment: A Longitudinal, Naturalistic Study
Mayouri Sukhapure,Kate Eggleston,Anna Fenton,Christopher Frampton,Richard J Porter,Katie M Douglas
DOI: https://doi.org/10.2147/NDT.S385014
IF: 2.989
2022-11-15
Neuropsychiatric Disease and Treatment
Abstract:Mayouri Sukhapure, 1, 2 Kate Eggleston, 1, 3 Anna Fenton, 4, 5 Christopher Frampton, 1 Richard J Porter, 1, 3 Katie M Douglas 1 1 Department of Psychological Medicine, University of Otago, Christchurch, Canterbury, New Zealand; 2 Centre for Healthy Brain Ageing, University of New South Wales, Sydney, New South Wales, Australia; 3 Specialist Mental Health Services, Canterbury District Health Board, Christchurch, Canterbury, New Zealand; 4 Department of Endocrinology, Canterbury District Health Board, Christchurch, Canterbury, New Zealand; 5 Oxford Women's Health, Christchurch, Canterbury, New Zealand Correspondence: Katie M Douglas, Department of Psychological Medicine, University of Otago, Christchurch, PO Box 4345, Christchurch, 8140, New Zealand, Tel +64 3 3726700, Fax +64 3 3720407, Email Purpose: Individuals with polycystic ovary syndrome (PCOS) are at increased risk of depression and anxiety symptoms and impairment in aspects of cognitive function. However, there is little evidence regarding effects of standard treatment for PCOS on these features of the syndrome. The aim of this study was to examine the effect of 12 weeks of naturalistic treatment of PCOS, with usual medications, on depression symptoms, anxiety symptoms and cognitive function. Patients and Methods: Thirty-three participants with PCOS received 12 weeks of individualised treatment based on clinical presentation. Changes in depression and anxiety symptoms were assessed with the self-report Hospital Anxiety and Depression Scale at baseline and 12 weeks, and cognitive function was assessed at the same time-points with a battery of tests spanning cognitive domains of verbal learning and memory, visuospatial learning and memory, psychomotor speed, attention and executive function. Outcomes were compared with a control group of 40 healthy participants. Results: Participants with PCOS (mean age = 29.2 years; mean Body Mass Index = 27.4) were treated with a variety of medications, predominantly spironolactone (n = 22) and oral contraceptives (n = 16). Depression and anxiety symptoms improved significantly over the course of treatment, with moderate effect sizes (Cohen's d 0.43– 0.55, p < 0.05). Effect sizes of the difference in change from that of the control group were moderate but did not reach statistical significance. Women undergoing PCOS treatment demonstrated significant improvements in aspects of cognitive function, but improvement did not differ significantly from controls and effect size changes were similar, suggesting practise effects in both groups. Conclusion: Our study provides preliminary evidence that treatment of PCOS may be associated with improvement in psychiatric aspects of the syndrome, particularly depressive symptoms. Keywords: androgen, depression, cognitive function, testosterone, spironolactone Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in premenopausal women. 1 Worldwide prevalence rates are between 5% and 10% depending on the diagnostic definition used, 2 and the economic impact is high, with a recent meta-analysis estimating the annual economic healthcare burden of PCOS was $8 billion in the United States. 3 It is a heterogenous disorder defined by a combination of signs and symptoms of androgen excess, oligo/anovulation and polycystic ovarian morphology. 4 PCOS is associated with psychiatric disorders, including mood and anxiety disorders. 5–8 Moderate-to-severe depression and anxiety symptoms are increased in women with PCOS compared with control groups in cross-sectional studies, 9,10 and longitudinal studies suggest increased risk of incident depression and anxiety. 11 As a result, screening for depression and anxiety has been recommended as a routine part of PCOS assessment, 12 and research into treatment for psychiatric aspects of PCOS has been identified as a priority. 6 There is preliminary evidence of cognitive impairment in women with PCOS compared with control participants, 13,14 which is unsurprising given that cognitive impairment is considered a core feature of depression. 15,16 Studies of cognitive function in samples with depression consistently find a broad range of cognitive functions impaired, including verbal and visuospatial learning and memory, executive functions, and psychomotor speed. 15 In anxiety disorders, impairment may still be evident across a number of domains, but can often be more circumscribed to attentional biases (to threatening stimuli) and memory dysfunction (working and episo -Abstract Truncated-
psychiatry,clinical neurology